The IDSA provides guidelines on the use and monitoring of vancomycin. [1]
References
- M.J. Rybak, J. Le, T.P. Lodise, D.P. Levine, J.S. Bradley, C. Liu, B.A. Mueller, M.P. Pai, A. Wong-Beringer, J.C. Rotschafer, K.A. Rodvold, H.D. Maples, and B.M. Lomaestro, "Therapeutic monitoring of vancomycin for serious methicillin-resistantStaphylococcus aureusinfections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists", American Journal of Health-System Pharmacy, vol. 77, pp. 835-864, 2020. http://dx.doi.org/10.1093/ajhp/zxaa036